Internal Medicine Alert – September 30, 2015
September 30, 2015
View Issues
-
SGLT2 Inhibitors: Now The Bad News
Sodium-glucose cotransporter-2 inhibitors are approved as adjunctive therapy for the treatment of patients with type 2 diabetes. This drug class has been also used off-label to improve glycemic control in patients with type 1 diabetes.
-
Is Low Testosterone Therapy Worth the Hype in the Elderly?
Testosterone replacement therapy showed no impact on subclinical atherosclerosis progression in recent study.
-
Migraine and Cognitive Dysfunction
During an attack of migraine without aura, patients may experience transient cognitive impairment, with predominant involvement of verbal processing speed, learning, and memory, due to reversible cortical dysfunction.
-
Alirocumab Injection (Praluent)
Alirocumab provides a new mechanism of action for lowering cholesterol in patients who have not achieved adequate lowering on maximum dose of statins.
-
Cryptogenic Stroke and Atrial Fibrillation
Recent study results support monitoring patients > 60 years of age with evidence of prior stroke on brain imaging to look for atrial fibrillation.
-
Clinical Briefs
In this issue: preventing recurrence of depression; predicting which patients with non-alcoholic fatty liver disease will progress; and treating premature ejaculation with tramadol.